PROLIFICA - West African Treatment Cohort for Hepatitis B

• Status: Completed
• Trial end date: 2018-07-31
• Target enrollment: 0
• Participant gender: All

Summary

The West African Treatment Cohort for Hepatitis B (WATCH) study is a component of the European Commission Funded FP7 project PROLIFICA. It aims to evaluate a number of steps required to successfully treat patients with chronic hepatitis B virus infection to prevent cirrhosis and liver cancer. The first step is to determine whether screening for hepatitis B using a point of care test is feasible and effective. The second is to monitor linkage from screening into care. The third is to evaluate cheap non-invasive assessments to determine the need for treatment. The fourth is to determine what proportion of patients meet treatment eligibility criteria. The fifth step is to establish a treatment cohort which can be used to measure adherence to therapy and avoidance of HBV related complications. A parallel untreated cohort will be established to determine whether treatment criteria are relevant in this West African setting by monitoring for complications of HBV infection.

• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Imperial College London
• Collaborators: Cheikh Anta Diop University, Senegal; Department of State for Health and Social Welfare, The Gambia; Institut National de la Santé Et de la Recherche Médicale, France; International Agency for Research on Cancer; Medical Research Council Unit, The Gambia; UFR Sante de Thies, Senegal
• Treatments: Tenofovir

Criteria

Inclusion Criteria:

• Adult Informed consent HBsAg positive Resident in Gambia or Senegal

Exclusion Criteria:

• HIV infection HCV infection Known liver cancer